- Horizon Discovery Group on Monday inked an exclusive partnership with C4X Discovery Holdings to deliver potential new drugs for patients with limited effective treatments such as colorectal and lung cancer.

C4XD would leverage its proprietary 4D shape-based chemistry technology, Conformetrix, to discover pre-clinical drug candidates using novel synthetic lethal oncology targets that Horizon had identified through its CRISPR-Cas9 technology.

The concept of harnessing synthetic lethality in cancer had been demonstrated with the recent approval of the ADP-ribose PARP inhibitors Lynparza, Zejula and Rubraca, Horizon said.

C4XD would fund the work plan and should C4XD discover pre-clinical drug candidates directed against these novel, synthetic lethality targets, it would out-license them to clinical development partners, and share the proceeds with Horizon, the company said.

'Drugging the cancer genome now requires new synthetic lethal therapies that can exploit the vulnerabilities in patient's tumours that are created by mutations in undruggable cancer driver gene. Horizon's internal research program has used powerful CRISPR technology to open a new window into how cancer cells are wired and has identified a cohort of novel targets,' said Dr Jon Moore, Horizon's Chief Scientific Officer.

'PARP inhibitors are transforming the treatment of ovarian cancer, particularly in patients with BRCA mutations and so identifying the next generation of synthetic lethality drug targets is a key priority to develop new therapies for cancers patients who are not responsive to current treatment,' said Dr Craig Fox, Chief Scientific Officer of C4XD.

At 8:40am: [LON:HZD] Horizon Discovery Group Plc share price was +4p at 172.5p

Story provided by